- Proton pump inhibitors like omeprazole, lansoprazole and pantoprazole reduce the acidity of the stomach and promote the healing of stomach ulcers
- Their long-term use has been associated with an increased risk of stomach cancer
- Further studies are required that are designed to specifically address the possible risk
The prolonged use of proton pump inhibitors following treatment for H. pylori infection of the stomach has been linked to an increased risk of stomach cancer. The study from Hong Kong was published in BMJ Gut.
Proton pump inhibitors, which include drugs like omeprazole, lansoprazole and pantoprazole, have been used for several years for the treatment of stomach ulcers. They bring about their effect by blocking a target called the proton pump in the inner lining of the stomach, thereby reducing the acid secretion by the stomach. They are included in the treatment regimen of Helicobacter pylori infection.
Helicobacter pylori or H. pylori is a bacterium that attaches to the inner layer of the stomach. Most patients with H. pylori in their stomachs do not suffer from any symptoms. Some people suffer from gastritis or stomach ulcers and even run a small risk of suffering from stomach cancer. The infection is treated with specific drug regimens that contain a proton pump inhibitor, at least two antibacterials and sometimes an additional drug.
Most patients took H2 blockers, while 5% took proton pump inhibitors for an average of around 3 years.
The risk of stomach cancer was more than double in the group taking proton pump inhibitors, while the increased risk was not noted in those taking H2 blockers
The risk increased with:
- A longer duration of use of proton pump inhibitors. The intake of the proton pump inhibitors for more than a year increased the risk 5 times, while an intake for three or more years increased the risk by more than 8 times
- More frequent use of proton pump inhibitors. The risk with the daily use of the proton pump inhibitors was around four times as compared to weekly use.
- Cheung KS, Chan EW, Wong AYS, et al Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study Gut. doi: http://dx.doi.org/10.1136/gutjnl-2017-314605
Please use one of the following formats to cite this article in your essay, paper or report:
Dr. Simi Paknikar. (2017, November 01). Long-term Proton Pump Inhibitor Use Associated With Stomach Cancer. Medindia. Retrieved on Sep 28, 2022 from https://www.medindia.net/news/healthinfocus/long-term-proton-pump-inhibitor-use-associated-with-stomach-cancer-174265-1.htm.
Dr. Simi Paknikar. "Long-term Proton Pump Inhibitor Use Associated With Stomach Cancer". Medindia. Sep 28, 2022. <https://www.medindia.net/news/healthinfocus/long-term-proton-pump-inhibitor-use-associated-with-stomach-cancer-174265-1.htm>.
Dr. Simi Paknikar. "Long-term Proton Pump Inhibitor Use Associated With Stomach Cancer". Medindia. https://www.medindia.net/news/healthinfocus/long-term-proton-pump-inhibitor-use-associated-with-stomach-cancer-174265-1.htm. (accessed Sep 28, 2022).
Dr. Simi Paknikar. 2021. Long-term Proton Pump Inhibitor Use Associated With Stomach Cancer. Medindia, viewed Sep 28, 2022, https://www.medindia.net/news/healthinfocus/long-term-proton-pump-inhibitor-use-associated-with-stomach-cancer-174265-1.htm.